Tirapazamine: a novel agent targeting hypoxic tumor cells (Q28302710)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Tirapazamine: a novel agent targeting hypoxic tumor cells (English)

0 references

0 references

Srini B Reddy

1

0 references

Stephen K Williamson

series ordinal

2

0 references

language of work or name

English

0 references

publication date

January 2009

0 references

published in

0 references

volume

18

0 references

issue

1

0 references

page(s)

77-87

0 references

cites work

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1517/13543780802567250

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Metabolism of tirapazamine by multiple reductases in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250

Cervix cancer oxygenation measured following external radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780802567250